AG
ALGS icon

Algert Global’s Aligos Therapeutics ALGS Stock Holding History

Algert Global’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-916
Closed -$272K – 1169
2021
Q4 		$272K Buy
916
+270
+42% +$98.5K 0.03% 767
2021
Q3 		$250K Buy
+646
New +$256K 0.03% 825

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Algert Global's ALGS Position: Q1 2022 in Review

Algert Global sold out of Aligos Therapeutics (ALGS) in Q1 2022, closing a stake of 916 shares — an estimated $272K sold.

Algert Global first reported a position in ALGS in Q3 2021 and held it in 2 quarters. The position peaked at $272K in Q4 2021. 76 funds tracked by Wall St. Rank hold ALGS as of Q1 2022.

  • Algert Global reported no remaining Aligos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Algert Global sold 916 Aligos Therapeutics shares in Q1 2022, an estimated $272K.
  • Algert Global first reported a position in Aligos Therapeutics in Q3 2021 and held it in 2 quarters.
  • Algert Global's Aligos Therapeutics position peaked at $272K in Q4 2021.
  • 76 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2022.

Based on Algert Global's 13F filing for Q1 2022, filed 16 May 2022.